AWM
BIOL

Apollon Wealth Management’s Biolase, Inc. BIOL Stock Holding History

Apollon Wealth Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed -$7K – 817
2022
Q1 		$7K Hold
8
– – ﹤0.01% 756
2021
Q4 		$8K Buy
+8
New +$10.1K ﹤0.01% 757

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Apollon Wealth Management's BIOL Position: Q2 2022 in Review

Apollon Wealth Management sold out of Biolase, Inc. (BIOL) in Q2 2022, closing a stake of 8 shares — an estimated $7K sold.

Apollon Wealth Management first reported a position in BIOL in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q4 2021. 16 funds tracked by Wall St. Rank hold BIOL as of Q2 2022.

  • Apollon Wealth Management reported no remaining Biolase, Inc. position as of Q2 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 8 Biolase, Inc. shares in Q2 2022, an estimated $7K.
  • Apollon Wealth Management first reported a position in Biolase, Inc. in Q4 2021 and held it in 2 quarters.
  • Apollon Wealth Management's Biolase, Inc. position peaked at $8K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2022.

Based on Apollon Wealth Management's 13F filing for Q2 2022, filed 11 Aug 2022.